Your AI-Trained Oncology Knowledge Connection!
Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.
A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.
Insights about PSA screening, genomics, and what's new in the areas of imaging, antiandrogen therapy, radiation therapy, immunotherapy, and radiopharmaceuticals will be offered during the 7th Annual IPCC.
New models have emerged for examining novel breast cancer treatments in the neoadjuvant setting that avoid the lengthy process of standard, large adjuvant trials.
In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings.
The first-line combination of trastuzumab and eribulin mesylate demonstrated an ORR of 71.2% with a median PFS of 11.6 months in patients with HER2-positive advanced breast cancer.
Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.
Success rates for lumpectomies or mastectomies are high with respect to survival, with up to 98% long-term survival rates for surgery and/or radiotherapy, but what if similar results could be achieved by substituting targeted medications for therapy?
The US Supreme Court's landmark decision last June, mandating that an individual's genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.
The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.
Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.
Over the past few decades, the optimal margin width for minimizing recurrence after breast-conserving surgery (BCS; lumpectomy) has been a topic of much debate
The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading
Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, describes oncoplastic surgery.
Hyman B. Muss, MD, discusses optimizing the administration of endocrine therapies with or without mTOR inhibitors for patients with HR-positive metastatic breast cancer
Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.
Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.
Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.
Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)
Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.
Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.
Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.
Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.